A Study to Learn How Different Tablets of the Study Medicine Mevrometostat Are Taken up Into the Blood in Healthy Adults
← catalyst calendarSponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 1
Status
Withdrawn
Study type
Interventional
Design
Randomized · None · Other
Enrollment
0actual
Sites
1
Country
Belgium
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
sponsor decision
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-04-28 | estimated | When the study began enrolling |
| Primary completion | 2025-09-08 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-09-09 | estimated | The whole study's end, after follow-up |
| First posted | 2024-10-28 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-04-24 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy
Interventions
- Drug: Treatment A — also filed as PF-06821497
- Drug: Treatment B — also filed as PF-06821497
- Drug: Treatment C — also filed as PF-06821497
- Drug: Treatment D — also filed as PF-06821497
Primary outcomes
what the primary-completion date above is the date OFMaximum Observed Plasma Concentration (Cmax) of Mevrometostat (Formulation 1)
measured Period 1-4: pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, and 72 hour(s) post-dose
Maximum Observed Plasma Concentration (Cmax) of Mevrometostat (Formulation 2)
measured Period 1-4: pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, and 72 hour(s) post-dose
Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of Mevrometostat (Formulation 1)
measured Period 1-4: pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, and 72 hour(s) post-dose
Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of Mevrometostat (Formulation 2)
measured Period 1-4: pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, and 72 hour(s) post-dose
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed